General Atlantic led a $225m Series B round in Seaport Therapeutics.

General Atlantic, a private equity firm, led a $225m Series B round in Seaport Therapeutics, a biopharmaceutical company that is advancing novel neuropsychiatric medicines, with participation from T. Rowe Price, Foresite Capital, Invus, Goldman Sachs Alternatives and CPP Investments. "We are grateful to have the partnership of this incredible group of new and existing investors who share our commitment of delivering better medicines for those suffering from depression, anxiety and other neuropsychiatric disorders. Seaport is advancing novel therapeutics that have proven clinical efficacy but had previously been held back by an issue we can now address with our Glyph platform. This financing enables the important clinical work that brings us another step closer to delivering new medicines to make a difference in the lives of patients and their families," Daphne Zohar, Seaport Therapeutics Founder and CEO.